Treatment of Elevated DHEA/DHEAS
The treatment of elevated DHEA or DHEAS depends entirely on identifying and addressing the underlying cause—isolated elevation without pathology typically requires no treatment, while androgen-secreting adrenal tumors require surgical resection.
Diagnostic Approach to Elevated DHEA/DHEAS
The first priority is determining whether the elevation represents a pathological process requiring intervention:
Rule Out Adrenal Malignancy
- Suspect adrenal carcinoma (ACC) when DHEAS is markedly elevated, particularly if accompanied by virilization symptoms in women (hirsutism, deepening voice, oligomenorrhea/amenorrhea) or feminization in men (gynecomastia, testicular atrophy) 1
- ACC should be strongly suspected in tumors >4 cm with irregular margins or internal heterogeneity on imaging 1
- Androgen-secreting tumors account for more than half of ACC cases with androgen hypersecretion 1
- Obtain comprehensive androgen panel including DHEAS, testosterone, 17β-estradiol, 17-OH progesterone, androstenedione, 17-OH pregnenolone, 11-deoxycorticosterone, progesterone, and estradiol when ACC is suspected 1
Imaging Evaluation
- Non-contrast CT is essential—measure Hounsfield units (HU) to assess lipid content 1
- Adrenal masses with HU ≥10 or unavailable HU measurements warrant screening for pheochromocytoma with plasma or 24-hour urinary metanephrines 1
- Contrast-enhanced CT helps assess washout characteristics and evaluate for metastases 1
- MRI with pituitary cuts if multiple hormonal abnormalities suggest pituitary pathology 1
Treatment Based on Etiology
Adrenal Carcinoma (ACC)
Surgical resection is the definitive treatment for androgen-secreting ACC:
- Open adrenalectomy is recommended for suspected malignancy, as these tumors are prone to rupture 1
- Malignancy indicators include: tumor >5 cm, inhomogeneous appearance with irregular margins, local invasion, or secretion of multiple hormones 1
- Complete imaging of chest, abdomen, and pelvis is required to evaluate for metastases before surgery 1
Benign Adrenal Adenomas
- Laparoscopic adrenalectomy is the treatment of choice for unilateral benign androgen-secreting adenomas when feasible 1
- Minimally invasive surgery (MIS) should be performed when feasible for functional adrenal masses 1
- Postoperative corticosteroid supplementation may be required until recovery of the hypothalamus-pituitary-adrenal (HPA) axis if concurrent cortisol suppression exists 1
Non-Pathological Elevations
No treatment is required for isolated DHEA/DHEAS elevation without:
- Adrenal mass on imaging
- Clinical signs of androgen excess
- Other hormonal abnormalities
Special Considerations
DHEA Replacement vs. Excess
The evidence provided discusses DHEA replacement therapy for deficiency states, which is the opposite clinical scenario:
- In primary adrenal insufficiency (PAI), women may benefit from DHEA replacement (10-50 mg daily, typically 25 mg) for persistent lack of libido or low energy despite optimized glucocorticoid/mineralocorticoid replacement 1
- DHEA replacement should be guided by serum DHEAS, androstenedione, and testosterone levels maintained in the normal range 1
- A pragmatic approach is a 6-month trial that can be continued if clinically effective 1
Metabolic Considerations
- Elevated DHEAS has been associated with increased risk for metabolic syndrome in elderly men (OR 2.68 for highest vs. lowest quartile) 2
- However, the relationship between DHEAS and cardiovascular disease remains uncertain and may vary by age, sex, and population 3
Common Pitfalls to Avoid
- Do not dismiss markedly elevated DHEAS without thorough imaging evaluation—very high levels are typical for adrenal tumors 4
- Do not perform laparoscopic surgery if malignancy is suspected; open adrenalectomy is required to prevent tumor rupture 1
- Do not confuse DHEA deficiency (requiring replacement) with DHEA excess (requiring evaluation for tumor) 1
- Ensure complete hormonal evaluation when adrenal mass is present, as tumors may secrete multiple hormones 1